Contineum Therapeutics Stock Price, News & Analysis

Contineum Therapeutics (Nasdaq: CTNM) announced a proposed underwritten public offering of $75.0 million of Class A common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million of shares, for potential gross proceeds of up to $86.25 million.

The offering is subject to market and other conditions and may not be completed. A related registration statement was filed May 14, 2025 and declared effective by the SEC on May 23, 2025. Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers.

Contineum Therapeutics (NASDAQ: CTNM) announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Wednesday, December 3, 2025 at 1:20 p.m. ET.

An audio webcast of the fireside chat will be available on the company’s Investor Relations website, and a webcast replay will be posted after the event.

Contineum Therapeutics (NASDAQ: CTNM) reported topline Phase 2 VISTA results for PIPE-307 on November 20, 2025.

The trial was a randomized, double-blind, placebo-controlled proof-of-concept study in relapsing-remitting multiple sclerosis (RRMS). The Company reported that PIPE-307 showed an acceptable safety and tolerability profile at both doses, but the study did not meet prespecified primary or secondary efficacy endpoints. Specifically, no significant change was observed in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms. Contineum said it will further interrogate exploratory endpoints, present the complete dataset at a future medical meeting, and publish full results in a peer-reviewed journal. Trial identifier: NCT06083753.

Contineum Therapeutics (NASDAQ: CTNM) reported third-quarter 2025 results and affirmed near-term clinical milestones. The company reported $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025, and says this cash runway now funds planned operations through 2028. Key clinical catalysts include anticipated topline data from the PIPE-307 Phase 2 VISTA RRMS trial in Q4 2025, initiation of a global PIPE-791 Phase 2 IPF trial in Q4 2025, and expected topline results from a PIPE-791 chronic pain Phase 1b trial in H1 2026. The company generated $19.0 million net proceeds from ATM equity sales in Q3 2025. Q3 operating expense trends: R&D was $11.0 million (+13% YoY) and G&A was $3.9 million (+21% YoY); net loss was $12.8 million.

Contineum Therapeutics (NASDAQ: CTNM) announced positive topline data from its Phase 1b PET trial of PIPE-791, a novel brain penetrant LPA1 receptor antagonist. The trial demonstrated that PIPE-791 achieved high brain receptor occupancy (RO) in both healthy volunteers and progressive multiple sclerosis (PrMS) patients.

Key findings include plasma EC50 values of 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, demonstrating sustained target engagement. The company expects planned doses for future Phase 2 trials in idiopathic pulmonary fibrosis (IPF) and PrMS to exceed 90% target coverage with once-daily dosing.

The trial involved 12 healthy volunteers and 4 PrMS patients, showing a clear correlation between drug exposure and receptor engagement, with a safety profile consistent with previous studies.

Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on neuroscience, inflammation and immunology (NI&I) therapies, has announced its participation in three major healthcare investor conferences in September 2025.

The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 4 at 9:10 a.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 8:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 at 2:00 p.m. ET. All presentations will be available via webcast on Contineum's investor relations website.

Contineum Therapeutics (NASDAQ: CTNM) has reported its Q2 2025 financial results and clinical development updates. The company ended Q2 with $175.5 million in cash and projects runway through 2027, supplemented by $8.4 million raised through ATM offering in July 2025.

Key milestones include anticipated topline data from PIPE-307 Phase 2 VISTA trial for multiple sclerosis in Q4 2025, and initiation of a global Phase 2 trial for PIPE-791 in idiopathic pulmonary fibrosis. The company reported a net loss of $16.0 million in Q2, with R&D expenses increasing 78% to $14.1 million year-over-year.

To optimize resources, Contineum has postponed its planned PIPE-791 Phase 2 trial in progressive multiple sclerosis and CTX-343 first-in-human studies to focus on the IPF program.

Contineum Therapeutics (NASDAQ: CTNM) has provided an update on its Phase 1b PET trial of PIPE-791, a selective LPA1 receptor antagonist. The company has completed enrollment for healthy volunteer and progressive multiple sclerosis (PrMS) cohorts, with 12 healthy volunteers and 4 PrMS patients enrolled to date.

The trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy using PET imaging. Due to the addition of two PrMS patients in early June, the company now expects to report topline data in Q3 2025, representing a modest delay. Enrollment for idiopathic pulmonary fibrosis (IPF) patients is still ongoing.

ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.

Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.